12 278

Cited 22 times in

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

Authors
Sohn, SK; Oh, SJ; Kim, BS; Ryoo, HM; Chung, JS; Joo, YD; Bang, SM; Jung, CW; Kim, DH; Yoon, SS; Kim, H; Lee, HG; Won, JH; Min, YH; Cheong, JW; Park, JS; Eom, KS; Hyun, MS; Kim, MK; Park, MR; Park, J; Kim, CS; Kim, HJ; Kim, YK; Park, EK; Zang, DY; Jo, DY; Moon, JH; Park, SY
Citation
Leukemia & lymphoma, 52(6):1024-1029, 2011
Journal Title
Leukemia & lymphoma
ISSN
1042-81941029-2403
Abstract
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with  <1000: 80.6% vs. 19.4%;  ≥ 1000: 94.6% vs. 5.4%; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with  <1000: 3.2% vs. 96.8%;  ≥ 1000: 21.4% vs. 78.6%; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of  ≥ 1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).
MeSH terms
AdolescentAdultAgedAntineoplastic Agents/adverse effects/pharmacokinetics/therapeutic useFemaleFusion Proteins, bcr-abl/geneticsHumansLeukemia, Myeloid, Chronic-Phase/*drug therapy/*geneticsLogistic ModelsMaleNeutropenia/chemically inducedPiperazines/blood/pharmacokinetics/*therapeutic useProspective StudiesPyrimidines/blood/pharmacokinetics/*therapeutic useReverse Transcriptase Polymerase Chain ReactionThrombocytopenia/chemically inducedTime FactorsTranscription, Genetic/drug effectsTreatment OutcomeYoung Adult
DOI
10.3109/10428194.2011.563885
PMID
21463107
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
박, 준성
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse